DRW Securities’s Calidi Biotherapeutics CLDI Stock Holding History

DRW Securities’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-147,767	Closed	-$173K	–	1353
2025 Q4	$173K	Buy	+147,767	New	+$217K	﹤0.01%	1001

Other funds holding CLDI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DRW Securities's CLDI Position: Q1 2026 in Review

DRW Securities sold out of Calidi Biotherapeutics (CLDI) in Q1 2026, closing a stake of 147,767 shares — an estimated $173K sold.

DRW Securities first reported a position in CLDI in Q4 2025 and held it in 1 quarter. The position peaked at $173K in Q4 2025. 28 funds tracked by Wall St. Rank hold CLDI as of Q1 2026.

DRW Securities reported no remaining Calidi Biotherapeutics position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 147,767 Calidi Biotherapeutics shares in Q1 2026, an estimated $173K.
DRW Securities first reported a position in Calidi Biotherapeutics in Q4 2025 and held it in 1 quarter.
DRW Securities's Calidi Biotherapeutics position peaked at $173K in Q4 2025.
28 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.